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Adenovirus (Ad) has been extensively studied as a eukaryotic viral vector. As these vectors have evolved from
first-generation vectors to vectors that contain either very few or no viral genes (“gutless” Ad), significant
reductions in the host innate immune response upon infection have been observed. Regardless of these vector
improvements an unknown amount of toxicity has been associated with the virion structural proteins. Here we
demonstrate the ability to generate high particle numbers (1011 to 1012) of Ad empty virions based on a
modification of Cre/lox gutless Ad vectors. Using a battery of analyses (electron microscopy, atomic force
microscopy, confocal images, and competition assays) we characterized this reagent and determined that it (i)
makes intact virion particles, (ii) competes for receptor binding with wild-type Ad, and (iii) enters the cell
proficiently, demonstrating an ability to carry out essential steps of viral entry. To further study the biological
impact of these Ad empty virions on infected cells, we carried out DNA microarray analysis. Compared to that
for recombinant Ad, the number of mRNAs modulated upon infection was significantly reduced but the
expression signatures were similar. This reagent provides a valuable tool for studies of Ad in that researchers
can examine the effect of infection in the presence of the virion capsid alone.
Adenovirus (Ad) vectors have evolved from first-generation
vectors where the transgene replaces only the E1 region to
vectors that contain either very few or no viral genes. In the
first-generation vectors, the deletion of E1 prohibits transacti-
vation of the viral genes that are required for viral replication.
Unfortunately, even in the absence of the E1 gene products,
there is residual expression of the remaining viral genes. This
expression results in an innate cytokine response and an anti-
gen-dependent immune response that includes cell-mediated
destruction of transduced cells (reviewed in reference 29),
resulting in limited transgene expression. These initial obser-
vations have led to the development of vectors containing
deletions of the E1 and E2 and/or E4 genes (1, 6, 19, 22) that
have shown reduced toxicity in animals. The adverse event in a
gene therapy trial using these vectors that resulted in a fatal
outcome (28) has demonstrated the importance of further
modifications before the vectors can be considered safe.
The major emphasis in the quest to develop Ad vectors that
demonstrate less toxicity has been to remove as much of the
viral genome as possible. Recent studies with Ad vectors that
do not contain any of the viral genome, “gutless” vectors,
demonstrate prolonged transgene expression with reduced im-
mune response against the virus itself (4, 5, 9, 21, 25). How-
ever, other studies have shown that psoralen- or UV-inacti-
vated viruses, with no de novo viral protein expression, can still
induce a cellular immune response (2, 15, 26). There are still
several possible mechanisms for the activation of adverse cel-
lular response after infection with these modified viruses.
These are (i) the primary process of infection, including bind-
ing to the cellular receptor, (ii) escape from the endosome by
capsid components, which reach the cytosol and enter the
major histocompatibility complex class I antigen-processing
pathway, and (iii) the presence of foreign DNA in the nucleus.
While data are accumulating, the exact role of each of these
components in the activation of immune response has yet to be
established.
Ideally, viral or vector gene expression and viral infection
should be uncoupled to understand the impact of Ad vectors
on cells and organisms. To achieve this goal, the ability to
generate a high-titer Ad vector completely devoid of viral
DNA is required. Genetic approaches to generating empty Ad
particles have been identified (8, 11, 12). The reagents involved
(temperature-sensitive and genetic mutants) have been ex-
tremely important for understanding Ad assembly. In fact
these mutants, although difficult to grow to extremely high
titer, provided the impetus to look for alternative ways to
produce high-titer empty particles. We have developed a
method for producing high-titer empty capsid Ad (eAd) based
on the Cre/lox gutless Ad vector production method (10, 23).
In addition, we have characterized the resulting eAd viral cap-
sids and determined that they (i) are nearly identical in phys-
ical characteristics, (ii) compete for receptor binding with the
wild type (wt), and (iii) enter the cell proficiently. Based on
these characterizations, these eAd viruses should be useful for
understanding the issues surrounding Ad vector infection. One
specific use for this type of reagent is to provide the ability to
monitor the cellular response to Ad vectors by DNA arrays,
comparing for the first time the role of viral infection in viral
gene expression.
Several methods for the production of eAd, including using
a mutant Ad with a temperature sensitivity mutation in the L1
52/55-kDa protein coding region (ts369), were evaluated (8,
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12). At the nonpermissive temperature empty capsids are pro-
duced, but in our hands not at very high titers, so a second
method was chosen. Empty Ad type 5 particles were made by
using a Cre/lox recombination system, specifically utilizing the
5 virus (it contains loxP sites flanking the DNA packaging
signal) typically used to make gutless vectors by supplying Ad
functions in trans (10). In CRE8 cells, expressing Cre recom-
binase, the DNA packaging site in 5 is deleted, thereby
preferentially packaging recombinant Ad (rAd) vector ge-
nomes into newly formed virions. To make a high-titer empty
capsid, the helper virus was used to infect CRE8 cells at an
multiplicity of infection (MOI) of 5 in the absence of coin-
fected rAd. After 48 h cells were harvested and lysates were
subjected to a step gradient with 1.2 and 1.4 g of CsCl/cm3 and
ultracentrifuged at 20,000  g for 2 h. In contrast to what was
found for wt Ad, two bands were observed with the majority of
material in the upper portion of the gradient. Both were har-
vested and characterized. Refractive indexes of the minor peak
indicated a density of approximately 1.32 g/cm3, and the den-
sity at the major peak was 1.29 g/cm3, consistent with that of wt
and empty Ad capsids (12). The peak at 1.29 g/cm3 was placed
on a continuous gradient at 1.295 g/cm3 and centrifuged at
38,000  g overnight. The band from this gradient was purified
on a third gradient and then dialyzed into phosphate-buffered
saline (PBS). To quantify yields of these empty capsid Ad
preparations, protein levels were measured by bicinchoninic
acid protein assay (Pierce) and sodium dodecyl sulfate-polyac-
rylamide gel electrophoresis (SDS-PAGE) and compared to an
Ad preparation of known titer. The rAd used in these exper-
iments (Ad-LacZ and Ad-green fluorescent protein [GFP])
was isolated as previously described and purified on a CsCl
gradient (14). Based on these analyses we were able to obtain
nearly identical amounts of empty and full virions (3.6  1012
particles of empty virions/ml compared to 4.2  1012 particles
of full virions/ml).
Further physical characterization of these empty particles
demonstrated the presence of all expected structural proteins.
Capsid proteins were separated by SDS-PAGE as described
previously (13). Virus was boiled in sample buffer for 10 min
and loaded onto a 12.5% polyacrylamide SDS-PAGE gel. The
gel was silver stained with the Silver Stain Plus kit (Bio-Rad)
according to manufacturer’s directions. In these preparations it
was apparent that polypeptides V and VII were missing from
eAd capsids (data not shown). These polypeptides are part of
the core protein of Ad, associated with the packaged viral
DNA, so it was not surprising that they are missing from the
empty particles. The rest of the capsid components appeared
to be present. A dot blot and ethidium bromide-stained aga-
rose gel were produced as previously described, and the results
indicated that DNA was not present in the eAd preparations
(data not shown).
Since both core proteins and viral DNA are missing from the
eAd preparations, both electron microscope (EM) and atomic
force microscope (AFM) images of the virus were made to
insure that intact virions were produced. The EM image (Fig.
1A) indicates that the empty capsids are predominantly intact;
however, there are much more viral debris and defective viral
particles than for rAd (Fig. 1B), indicating that the empty
capsid virus shell may be less stable than virus containing DNA
and core proteins. Based on sized and shape, the debris ap-
pears to be composed mostly of hexon subunits. The empty
capsids also appear to be much more rounded and much less
compact (12). Since the core proteins and the DNA are miss-
ing from the empty capsids, these proteins may serve to stabi-
lize and provide structure to the virus by electrostatic interac-
tions with other capsid components, leading to its
characteristic icosahedral appearance, density, and stability.
This is consistent with observations of viral protein exchanges
concomitant with DNA entry (20). AFM was performed to
obtain information about surface characteristics of the Ad viri-
ons and a more accurate size measurement. In the AFM im-
ages the eAd is slightly larger, based on the amount of debris,
and appears more fragile than the rAd (Fig. 2), similar to what
was observed in the EM images. The average height of the eAd
was 68 nm versus 55 nm for the rAd (Fig. 2). The debris in both
images indicates that the eAd may break apart more readily
than the Ad, which may be an artifact of preparation for EM
and AFM. Regardless, these images demonstrate the produc-
tion of predominantly intact virus by this method.
To demonstrate that empty particles infect cells, we showed
that eAd competitively inhibits the transduction of cells by
rAd-GFP, indicating that some of its interactions with the cell
are similar to those of rAd. The eAd was mixed in increasing
concentrations with rAd-GFP to determine if eAd could block
FIG. 1. EM of rAd and eAd. Suspensions of virus were examined
by transmission EM using a negative-stain technique. A glow-dis-
charged Pioloform-filmed 400 mesh nickel grid was placed film side
down onto a 10-m drop of viral suspension for 10 min to allow for
particle adsorption. The grid was rinsed briefly to remove buffer salts
by floating on 2 drops of distilled H2O and stained by transferring it to
a drop of 2% aqueous uranyl acetate, pH 3.5 (or 2% potassium phos-
photungstate, pH 7.0), for 1 min. The stained grids were air dried and
examined at an accelerating voltage of 80 keV in a LEO EM-910
transmission EM (LEO Electron Microscopy, Inc., Thornwood, N.Y.).
Magnification, 160,000. Two populations of virus are apparent here.
(A) Empty particles; (B) rAd.
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the entry of normal recombinant virus at high concentrations
(Fig. 3). This was measured by evaluating transduction of em-
bryonic lung fibroblasts by the rAd-GFP in the presence of
competing virus. These data were compared to experiments
where particle numbers of rAd-LacZ equal to particle numbers
of eAd were also used for competition. After 24 h the number
of GFP-expressing cells was evaluated and was shown to de-
crease as more eAd or rAd-LacZ was added to the virus mix-
ture (Fig. 3). This was expressed as percent inhibition of trans-
duction with rAd-GFP and is the ratio of transduced cells with
competitor virus present to the control with no competing
virus. The results indicate that the eAd can compete with
rAd-GFP for receptor binding and reduce its ability to trans-
duce cells. When rAd-LacZ was used as the competitor the
results were similar, although the rAd-LacZ appears to be a
slightly more effective competitor (by less than twofold; Fig. 3).
This experiment provides a demonstration of competitive in-
hibition of binding to the cellular receptor but does not supply
direct evidence that the empty particle can enter cells.
To obtain direct evidence that eAd enters cells, eAd was
labeled with Cy3 and used to infect lung fibroblasts. A Cy3
fluorescent label was conjugated to the empty capsid Ad (Cy3-
eAd), purified, and then used to infect cells. Approximately 5
 1012 empty particles were dialyzed into PBS containing 10%
glycerol with three changes of buffer. Two hundred microliters
of a 1-mg/ml solution of an N-hydroxysuccinimide ester of
FluoroLink Cy3 (Amersham Life Science) was made up in 0.1
M carbonate buffer, pH 9.3, and added to 1 ml of Ad. This
FIG. 2. AFM of rAd and eAd. The silicon substrate surface with
intact native oxide was prepared by UV cleaning, rinsing with distilled
H2O (dH2O), and drying under a filtered-nitrogen stream. Approxi-
mately 15 l of solution of 1011 Ad particles/ml was deposited on the
above surface, and viruses were allowed to adsorb for 15 min. Un-
bound viruses were removed by washing with dH2O and then dried
under a nitrogen stream. Imaging was performed in air with a Ther-
moMicroscopes Explorer (Veeco/TM, Sunnyvale, Calif.) with a
100-m tripod air scanner calibrated with a NT-MDT calibration grid.
Silicon tips (Nanosensors FESP; Digital Instruments, Santa Barbara,
Calif.) with spring constant of 2 N/m and resonance frequency of
70 kHz were used for imaging in intermittent-contact mode.
(A) rAd; (B) empty particles.
FIG. 3. Competition of eAd with rAd. Ad mixtures with approxi-
mately 5  105 rAd-GFP particles were incubated with 105 IMR-90
cells at 4°C for 1 h to allow virus attachment in cold DMEM with 2%
FCS. The cells were then washed three times in ice-cold PBS to
remove unattached virus. DMEM with 10% FCS was then added, and
cells were placed at 37°C in 5% CO2. At 24 h cells were examined for
GFP expression by fluorescence microscopy with a fluorescein isothio-
cyanate filter. GFP-expressing cells were counted, and duplicate ex-
periments yielded similar results. IMR-90 cells were demonstrated to
express the Ad receptor, CAR, on their surface by immunohistochem-
istry (data not shown).
FIG. 4. Internalization of eAd. For internalization studies IMR-90
cells were grown on eight-well chamber slides (LabTech II) and then
infected with Cy3-labeled Ad (red) at approximately 10,000 particles
per cell. Cells were fixed at 6 h p.i. with 4% paraformaldehyde in PBS
for 15 min. They were then mounted with Vectashield containing
DAPI to label nuclei (blue) (Vector Laboratories, Burlingame, Calif.).
Internalization was assessed by confocal microscopy with a Zeiss
CLSM 210 confocal laser scanning microscope with a UV laser.
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mixture was incubated at room temperature for 2 h in the dark
(17). This solution was then dialyzed into a solution containing
10 mM Tris, pH 7.8, 140 mM NaCl, 1 mM MgCl2, and 10%
glycerol. Virus was removed from the dialysis chamber, ali-
quoted, and stored at 20°C. Previous studies have deter-
mined that these modifications reduce Ad infectivity titer by
less than 10-fold, so MOIs were adjusted accordingly (16, 24).
Embryonic lung fibroblast cells were exposed to Cy3-eAd for
1 h at 4°C for viral binding and then washed extensively before
incubation at 37°C for 6 h. As previously described (17) the
cells were then fixed and viewed in cross sections by confocal
microscopy (Fig. 4). The nucleus was counterstained with
DAPI (4,6-diamidino-2-phenylindole). Labeled virus was ob-
served in the centers of the infected cells but not in the nuclei
as previously described (7, 27), providing direct evidence that
these empty particles are capable of entering cells. Taken to-
gether these results indicate that eAd can bind the cell surface
in a receptor-mediated manner and enter IMR-90 cells, indi-
cating that these particles are a suitable reagent for studying
the impact of the Ad virion shell during infection.
To evaluate these particles for impact of cellular function in
the absence of viral DNA, we analyzed IMR-90 cells after
infection using Affymetrix GeneChip arrays. Cells were in-
fected with rAd while they were below confluence at an MOI
of infectious virus of 250 to 500. Since particle numbers were
determined by protein measurement and since EM analysis
indicated the presence of viral debris, we used a higher relative
MOI of empty particles in these experiments (MOI, 2,500).
Additionally, the competition experiment indicated that if
MOIs of rAd-LacZ of 250 to 500 were used, approximately
10-fold-higher levels of eAd were required to achieve the same
percentage of competition with rAd-GFP. Comparable vol-
umes of material from mock virus preparations were added to
cells for controls. Cells were placed in Dulbecco’s modified
Eagle medium (DMEM) with 2% fetal calf serum (FCS) dur-
ing infection for 1 h at 4°C for virus binding, and then cells
were washed, the appropriate growth medium was added, and
the cells were placed at 37°C in 5% CO2. Infected cells were
collected at 24 h postinfection (p.i.) and lysed, and total RNA
was isolated with an RNeasy kit according to manufacturer’s
directions (Qiagen). Approximately 10 g of isolated total
RNA was used to generate biotin-labeled cRNA as described
previously (18). This was fragmented and hybridized to Gene-
Chip arrays and then installed in a fluidics station (Affymetrix)
for washing and staining as previously described. Arrays were
read twice with a Hewlett-Packard GeneArray scanner. Data
were collected and analyzed with GeneChip expression analy-
sis software. The Affymetrix GeneChip used for this analysis
was the HL6800 containing 5,600 human expressed sequence
tags. Details of the data analysis have been previously de-
scribed (18).
When differential levels of cellular gene expression in eAd-
TABLE 1. Genes modulated by eAd and rAd at 24 h p.i.
Encoded protein Genbankaccession no. Class or function
b
Fold changea in expression
due to:
eAd rAd
GTP-binding protein U10550 2.3 2.7
Transcription factor 7 X59871 2.2 3.1
Interferon-induced protein 56 M24594 1.8 5.9
Zinc finger protein 161 D28118 1.7 1.8
c-Jun J04111 2.0 5.8
JunB X51345 2
Early growth response 1 X52541 2 4.7
MEKK4 D86968 2.1 1.7
Growth arrest damage-inducible 153 S40706 5.4 42.5
Hypoxia-inducible factor 1 U22431 1.7 2
Heat shock protein 70 kDa 1A M11717 1.9 2.8
Zinc finger protein mel-18 D13969 2.3
Zinc finger protein 36 X78992 8.8
Zinc finger protein 91 L11692 2
Splicing factor 1 Y08766 2.2
DEAD/H box polypeptide 21 U41387 2.6
DEAD/H box polypeptide 38 U90426 2
Splicing factor 3a X85237 2.1
a A  in front of a value indicates that the transcripts in one of the samples did not register as present and therefore the change was calculated against background.
b Red, immune response; blue, stress response; green, transcriptional regulation; purple, RNA processing.
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and rAd-infected cells were compared, we observed that the
removal of the viral genome eliminated the modulation in
expression of many cellular genes (147 and 476, respectively,
were modulated by twofold or more; for the entire data set go
to http://www.med.unc.edu/genether/). When IMR-90 cells
were infected with rAd, two clusters of mRNAs related to the
immune response and stress response increased in concentra-
tion. A subset of these increased in concentration in eAd-
infected cells (Table 1). Two other clusters, related to tran-
scription regulation and RNA-processing genes, were observed
in eAd-infected cells but not in rAd-infected cells. This is of
interest because one would expect that the Ad capsid would
only modulate a subset of genes observed in rAd infection.
However, this difference may represent an activity of the wt
virus or vector, through expression of its genome, to repress
some of the events that the viral capsid sets in motion. This
type of phenomenon has been observed with human cytomeg-
alovirus (HCMV), where viral gene products block antiviral
pathways that are triggered by HCMV binding and entry (3).
This reagent provides a critical tool for studies of Ad where
researchers can examine the effect the virion shell on viral
infection alone. In the past psoralen- and UV-treated viruses
have been used to eliminate viral gene expression for these
types of studies. It is not clear if all viral gene expression is
eliminated by these treatments or if the treatments themselves
altered the virus in ways that obscure the influence of viral
capsid components or infection. The eAd reagent is not only
useful for studies like the one described here but also has the
potential to become a beneficial tool for animal studies de-
signed to examine the toxicity of the capsid components of Ad.
A database established from in vitro and in vivo studies using
empty capsid Ad particles will be essential for future vector
design where capsid mutations intended to mitigate unwanted
effects are assayed.
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